Ketamine holds promise for people with treatment-resistant depression
Washington: In a new study, patients with treatment-resistant major depression saw dramatic improvement in their illness after treatment with ketamine, an anesthetic.
The largest ketamine clinical trial to-date was led by researchers from the Icahn School of Medicine at Mount Sinai.
The antidepressant benefits of ketamine were seen within 24 hours, whereas traditional antidepressants can take days or weeks to demonstrate a reduction in depression.
Led by Dan Iosifescu, MD, Associate Professor of Psychiatry at Mount Sinai; Sanjay Mathew, MD, Associate Professor of Psychiatry at Baylor College of Medicine; and James Murrough, MD Assistant Professor of Psychiatry at Mount Sinai, the research team evaluated 72 people with treatment-resistant depression-meaning their depression has failed to respond to two or more medications-who were administered a single intravenous infusion of ketamine for 40 minutes or an active placebo of midazolam, another type of anesthetic without antidepressant properties.
Patients were interviewed after 24 hours and again after seven days. After 24 hours, the response rate was 63.8 percent in the ketamine group compared to 28 percent in the placebo group. The response to ketamine was durable after seven days, with a 45.7 percent response in the ketamine group versus 18.2 percent in the placebo group. Both drugs were well tolerated.
"Ketamine continues to show significant promise as a new treatment option for patients with severe and refractory forms of depression," said Dr. Murrough, who is first author on the new report.
Major depression is caused by a breakdown in communication between nerve cells in the brain, a process that is controlled by chemicals called neurotransmitters. Traditional antidepressants such as selective serotonin reuptake inhibitors (SSRIs) influence the activity of the neurotransmitters serotonin and noreprenephrine to reduce depression.
In these medicines, response is often significantly delayed and up to 60 percent of people do not respond to treatment, according to the U.S Department of Health and Human Services. Ketamine works differently than traditional antidepressants in that it influences the activity of the glutamine neurotransmitter to help restore the dysfunctional communication between nerve cells in the depressed brain, and much more quickly than traditional antidepressants.
Future studies are needed to investigate the longer term safety and efficacy of a course of ketamine in refractory depression.
Dr. Murrough recently published a preliminary report in the journal Biological Psychiatry on the safety and efficacy of ketamine given three times weekly for two weeks in patients with treatment-resistant depression.
"We found that ketamine was safe and well tolerated and that patients who demonstrated a rapid antidepressant effect after starting ketamine were able to maintain the response throughout the course of the study," Dr. Murrough said.
"Larger placebo-controlled studies will be required to more fully determine the safety and efficacy profile of ketamine in depression," he added.
The research will be discussed at the American Psychiatric Association meeting on Monday, May 20, 2013 at 12:30 pm in the Press Briefing Room at the Moscone Center in San Franscico.
More from India
More from World
More from Sports
More from Entertaiment
- Heat ave continues in India, death toll climbs to over 1,400
- Megastar Amitabh Bachchan slapped with Rs 1 crore notice
- Kenyan lawyer offers to marry Barack Obama's daughter Malia
- Salman Khan accident files burnt in Mantralaya fire
- Maggi likely to face ban in India!
- TERI panel finds RK Pachauri guilty in sexual harassment case
- Rajasthan: High Court raps Chief Secy, DGP for failing to end Gujjar agitation
- Meet 92-year-old Phyllis Sues who dances toTango
- Erstwhile Mysuru kingdom gets new king
- Priyanka, Ranveer talk about their film 'Dil Dhadakne Do'
- Former Bihar CM Jitan Ram Manjhi meets PM Modi
- Street food in Delhi contains high levels of faecal matter
- DNA: Pentagon report says Beijing accelerates land reclamation in South China Sea
- Aapke Sitare: Astro prediction for May 28, 2015
- Watch: ISIS prisoner digging his own grave
- CBSE Class 10 (Class X Board) Result 2015 on cbse.nic.in, cbseresults.nic.in at 2 pm
- GUJCET Results 2015 declared on gseb.org
- Check cbseresults.nic.in, cbse.in for CBSE Class 10 X Board Result at 2 pm
- Rahul Gandhi takes another dig at NDA govt, says Manmohan gave lessons on economy to PM Modi
- Centre moves SC against Delhi HC order on LG's powers; hearing on Friday
- Gujjar agitation: Centre sending additional forces to vacate rail tracks, say sources
- Log on to cbseresults.nic.in, cbse.nic.in at 2 pm for Class 10th Result 2015
- WBCHSE (wbchse.nic.in & wbresults.nic.in): West Bengal Class 12th Result to be declared on May 29
- Delhi HC backs LG, turns down plea challenging Jung's authority
- Gujarat Board Results 2015: Gujarat Board HSC class 12th science results to be declared today at 9 AM on gseb.org
- Former Bihar CM Jitan Ram Manjhi meets PM Modi, triggers tie-up speculation
- CBSE (cbseresults.nic.in, cbse.nic.in) Class 10th (X Board) Result 2015 declared
- CBSE Board Results 2015: Class 10 Results to be declared on May 28 on cbse.nic.in
- Heatwave toll in Andhra Pradesh reaches 1,490
- Maggi noodles likely to face ban in India, FSSAI orders sample examination